Daytime sleepiness in patients with obstructive sleep apnea and associated comorbidities
Abstract
Introduction: Obstructive sleep apnea (OSA) is characterized by recurrent upper-airway collapse during sleep, leading to ineffective respiratory efforts, intermittent hypoxia, and sleep fragmentation. Patients with OSA often have comorbid conditions. Excessive daytime sleepiness (EDS), defined as an inability to remain awake during the day, is common among patients with OSA; however, its perception may vary with comorbidities that affect autonomic and neuroendocrine regulation.
Areas covered: We reviewed studies examining the prevalence and clinical impact of EDS in patients with OSA and its main comorbidities, published between January 2000 and September 2025, and identified through Medline.
Expert opinion: EDS is highly prevalent in patients with OSA and arterial hypertension, cardiac arrhythmias, cerebrovascular comorbidities (particularly in those with thalamic or pontine lesions), diabetes mellitus, metabolic syndrome, asthma, chronic kidney disease, and cancer. By contrast, EDS appears less prevalent in patients with heart failure, treated cerebrovascular and neurodegenerative disease (particularly in those receiving levodopa, selective serotonin reuptake inhibitors, or bromocriptine), and chronic obstructive pulmonary disease (COPD).In conclusion, in patients with OSA, EDS is perceived differently depending on comorbidity. Consequently, EDS assessment should follow a personalized, multidimensional approach that recognizes its clinical relevance while accounting for…
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.